Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04456608 · ClinicalTrials.gov registry record · Phase 4
Genetic and Dietary Predictors of Anti-platelet Response
A Phase 4 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 4
- Development phase
- 126
- Enrollment target
NCT04456608 is a Phase 4 study that was terminated before completion, run by University of Washington. The registered enrollment target is 126 participants.
The verdict
NCT04456608, a Phase 4 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 126 participants
- Enrollment target
Study Summary
This study will investigate differences in platelet aggregation under basal and aspirin-treated conditions in American Indian and Alaska Native people who have extreme levels (low and high) of n-3 polyunsaturated fatty acids (n-3 PUFAs, EPA and DHA) in red blood cell membranes. The study will also determine whether or not platelet aggregation under the different conditions is modified by CYP4A11, CYP4F2, CYP4F11, PEAR1, and ACTN1 gene variation.
Interventions
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2023-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04456608
The ClinicalTrials.gov registry entry for NCT04456608 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspirin is the first listed.
NCT04456608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04456608 about?
NCT04456608 is a clinical study titled "Genetic and Dietary Predictors of Anti-platelet Response". This study will investigate differences in platelet aggregation under basal and aspirin-treated conditions in American Indian and Alaska Native people who have extreme levels (low and high) of n-3 polyunsaturated fatty acids (n-3 PUFAs, EPA and DHA) in red blood cell membranes. The study will also d...
What is the current status of trial NCT04456608?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 126 participants. The study started on 2016-08-01. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT04456608?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT04456608?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.